-
Mitigating the Prozone‐Like Effect in HLA Antibody Testing: A Case Report of Therapeutic Plasma Exchange for Antibody‐Mediated Rejection Post‐Heart Transplantation J. Clin. Apher. (IF 1.4) Pub Date : 2024-09-18 Sarah K. Grewal, Robert Achram, Hirotomo Nakahara, John D. Roback, Anna B. Morris, Howard M. Gebel, Robert A. Bray, H. Cliff Sullivan
Therapeutic plasma exchange (TPE) is a cornerstone treatment for antibody‐mediated rejection (AMR) post‐organ transplantation, aiming to eliminate pathogenic donor‐specific HLA antibodies (DSA). However, limitations in HLA antibody interpretation due to the prozone‐like effect (PLE) can lead to inaccurate assessment of treatment efficacy. We present a case of a heart transplant recipient with suspected
-
Preemptive Approach to Plerixafor Use Is Optimal in Patients With Relapsed/Refractory Germ Cell Tumors Undergoing Peripheral Blood Hematopoietic Stem Cell Collection: Effect on Collection Days, Yields, and Cost J. Clin. Apher. (IF 1.4) Pub Date : 2024-09-18 David O. Sohutskay, Anne M. Tetrick, W. Scott Goebel, Dave Schwering, Manasa S. Reddy
Evidence describing the use of plerixafor in the off‐label population of relapsed/refractory germ cell tumors (GCT) is limited. We aim to describe the effect of rescue versus preemptive plerixafor use on apheresis collection days, collection yields, and cost. We retrospectively collected data on 77 consecutive patients (at least 15 years of age) with GCT who underwent peripheral blood stem cell (PBSC)
-
-
Comparative efficacy of double plasma molecular adsorption system combined with plasma exchange versus plasma exchange in treating acute‐on‐chronic liver failure due to hepatitis B: A meta‐analysis J. Clin. Apher. (IF 1.4) Pub Date : 2024-08-27 Le Zhang, Yan Ma, Xia Wang, Li‐Na Ma, Wanlong Ma, Xiang‐Chun Ding
This meta‐analysis aims to evaluate the effectiveness of the double plasma molecular adsorption system (DPMAS) in combination with plasma exchange (PE) compared to plasma exchange alone in the treatment of Acute‐on‐Chronic liver failure (LF) caused by hepatitis B. Until August 31, 2023, a comprehensive search of databases including Embase, Chinese Medical Journal Full‐text Database, China Biomedical
-
Use of a novel configuration of ports for patients needing intermittent long‐term apheresis J. Clin. Apher. (IF 1.4) Pub Date : 2024-08-06 Matthew S. Howlett, Kimani Hicks, Yara Park, Matthew S. Karafin, Peter R. Bream
PurposeIn patients with a need for frequent but intermittent apheresis, vascular access can prove challenging. We describe the migration of the use of a Vortex LP dual lumen port (Angiodynamics, Latham, NY) to one Powerflow and one ClearVUE power injectable port (Becton Dickinson, Franklin Lakes, NJ) in a series of patients undergoing intermittent apheresis.Materials and MethodsAll patients had a need
-
A rare case of acute cerebellitis due to enterovirus treated with therapeutic plasma exchange: Case report and review of the literature J. Clin. Apher. (IF 1.4) Pub Date : 2024-08-02 Nihal Akçay, Neval Topal, Seda Yılmaz Semerci
BackgroundAcute cerebellitis is a rare complication of pediatric infections. There are many reports that viral infections lead to neurological manifestations, including acute cerebellitis.MethodsA retrospective chart review was conducted for pediatric patients diagnosed with enterovirus cerebellitis between 2000 and 2024. The methods involved reviewing clinical and radiological records and assessing
-
Effects of Rheopheresis in dialysis patients with peripheral artery disease and diabetic foot ulcers: A multicentric Italian study. J. Clin. Apher. (IF 1.4) Pub Date : 2024-08-01 Claudia Altobelli,Filippo Carone Fabiani,Pietro Anastasio,Corrado Pluvio,Emanuela de Pascale,Luigi Vernaglione,Giuseppe Gernone,Marina Di Luca,Veronica Bertuzzi,Paola Brescia,Pierpaolo Toffoletto,Mario D'Arezzo,Maddalena Brustia,Andreana De Mauri,Doriana Chiarinotti,Carmelo Loschiavo,Matteo Grecò,Filomena D'Elia,Maria Anna Gallo,Giovanni Tarroni,Lorenzo Di Liberato,Alessandra F Perna,Giovambattista
BACKGROUND Peripheral artery disease (PAD) in hemodialysis (HD) patients has a significant social impact due to its prevalence, poor response to standard therapy and dismal prognosis. Rheopheresis is indicated by guidelines for PAD treatment. MATERIALS AND METHODS Twenty-five HD patients affected by PAD stage IV Lerichè-Fontaine and ischemic ulcer 1C or 2C according to the University of Texas Wound
-
Small but mighty: Case report and practical guidance for peripheral blood stem cell collection in small infants J. Clin. Apher. (IF 1.4) Pub Date : 2024-07-27 Hannah Walker, Erin O'Reilly, Zoe Millard, Brendan Cusack, Anna Duncan, Luisa Clucas, Jacqueline Fleming, David Hughes, Anthea Greenway, David Metz
Modern apheresis devices, with increased procedural precision, automation, and monitoring, have been shown to allow for safe delivery of apheresis therapies in young children. Medical advances are increasing demand for apheresis procedures like mononuclear cell collection in infants <10 kg, including stem‐cell supported chemotherapy, cell collection for chimeric antigen receptor T cell development
-
Telapheresis: One institution's experience J. Clin. Apher. (IF 1.4) Pub Date : 2024-07-10 Mehraboon Irani, Sorelle Jefcik, Susan Knight
Telemedicine in its most common form is the use of videoconferencing to consult with a patient and telapheresis is telemedicine in the form of videotelephony applied to consult with a patient for apheresis. The article discusses how a large apheresis program in a metropolitan area provided physician coverage for apheresis in a more remote hospital using telapheresis with local physician “partners”
-
A multi‐institutional survey of apheresis services among institutions in the United States J. Clin. Apher. (IF 1.4) Pub Date : 2024-07-09 Nalan Yurtsever, Jeremy W. Jacobs, Garrett S. Booth, Joseph Schwartz, Yara A. Park, Jennifer S. Woo, Deisen Lauro, Sarina Torres, Dawn C. Ward, Laura D. Stephens, Elizabeth S. Allen, Christopher A. Tormey, Brian D. Adkins
IntroductionApheresis practices in the United States (US) have not been comprehensively characterized to date. This study aimed to address this gap by evaluating apheresis therapy through a national survey.MethodsA multi‐institutional survey was conducted between April and July 2023. The survey, comprising 54 questions, focused on institutional demographics, procedures, equipment, staffing, training
-
-
Therapeutic plasmapheresis in idiopathic membranous nephropathy anti‐PLA2R‐related: A case series J. Clin. Apher. (IF 1.4) Pub Date : 2024-06-27 Dario Musone, Valentina Nicosia, Riccardo D'Alessandro, Marco Andrietti, Paolo Francesco Steri, Carolina Ruosi, Sofia Giuliana, Claudia Elefante, Pina Cuccurullo, Antonio Treglia
Membranous nephropathy is the most common cause of nephrotic syndrome (NS) in non‐diabetic adults; in 80% of patients it is idiopathic (PMN). PMN has an autoimmune pathogenesis, 70%‐85% of patients have increased titer of antibodies to the podocyte membrane antigen PLA2R. The etiological, prognostic and predictive role of the Ab anti‐PLA2R is demonstrated. Standard therapy consists in anti‐CD20 monoclonal
-
Immunogenicity of SARS‐CoV‐2 vaccines in patients treated with chronic double filtration plasmapheresis J. Clin. Apher. (IF 1.4) Pub Date : 2024-06-26 Emilie Pambrun, Paul Loubet, Thomas Fourneron, Olivier Moranne
BackgroundThe impact of chronic therapeutic plasmapheresis on humoral response following COVID‐19 vaccination is poorly documented, especially among patients treated with double filtration plasmapheresis (DFPP).ObjectivesThis retrospective single‐center study evaluated the humoral response after SARS‐CoV‐2 vaccination and studied anti‐SPIKE seropositivity and antibody dynamics in patients with chronic
-
CD34+ cell yield among healthy donors: Large‐scale model development and validation J. Clin. Apher. (IF 1.4) Pub Date : 2024-06-26 Abdullah Alswied, David Daniel, Leonard N. Chen, Tariq Alqahtani, Kamille Aisha West‐Mitchell
BackgroundSuccessful engraftment in hematopoietic stem cell transplantation necessitates the collection of an adequate dose of CD34+ cells. Thus, the precise estimation of CD34+ cells harvested via apheresis is critical. Current CD34+ cell yield prediction models have limited reproducibility. This study aims to develop a more reliable and universally applicable model by utilizing a large dataset, enhancing
-
Therapeutic plasma exchange as treatment modality in pediatric patients with neurologic and nonneurologic diseases at the Philippine Children's Medical Center: A 12‐year single center experience J. Clin. Apher. (IF 1.4) Pub Date : 2024-06-22 Alexander B. Suplico Jr, Maria Beatriz P. Gepte
ObjectiveTo determine the clinical characteristics, indications, technical aspects, complications, and outcomes of therapeutic plasma exchange (TPE) procedures performed in pediatric patients with neurologic and nonneurologic diseases at the Philippine Children's Medical Center during a 12‐year period (January 2010–March 2023).Materials and MethodsAll TPE performed between January 2010 and March 2023
-
Interest of therapeutic plasmapheresis in a chronic hemodialysis patient with severe bullous pemphigoid. J. Clin. Apher. (IF 1.4) Pub Date : 2024-06-01 Pedram Ahmadpoor,Mathilde Beck,Moise Michel,Emilie Pambrun,Pierre Stoebner,Olivier Moranne
Bullous pemphigoid is the most common autoimmune blistering disease induced by autoantibodies against basement membrane anchoring proteins (anti-BP-180 and anti-BP-230). The disease generally appears after the age of 70 and is associated with a 23.5% 1-year mortality, especially in diabetics, or in the presence of ischemic heart disease and high anti-BP-180. Treatment starts with topical steroids but
-
Comparison of efficacy of plasma exchange versus intravenous immunoglobulin as an add-on therapy in acute attacks of neuromyelitis optica spectrum disorder. J. Clin. Apher. (IF 1.4) Pub Date : 2024-06-01 Garima Siwach,Rekha Hans,Aastha Takkar,Chirag Kamal Ahuja,Divjot Singh Lamba,Vivek Lal,Ratti Ram Sharma
INTRODUCTION Plasma exchange (PE) is considered a Category II option for the treatment of acute attacks and relapse cases of neuromyelitis optica spectrum disorder (NMOSD). However, neurologists are also considering intravenous immunoglobulins (IVIg) as an add-on therapy for this disorder. AIMS The aim of this study is to evaluate the efficacy of PE in acute attacks of NMOSD when compared with IVIg
-
Therapeutic plasma exchange combined with ribavirin to rescue critical SFTS patients. J. Clin. Apher. (IF 1.4) Pub Date : 2024-06-01 Xuezhen Song,Xiaojun Xu,Xiaoning Ren,Xiaoxuan Ruan,Jinshuang Bo
BACKGROUND Severe fever with thrombocytopenia syndrome (SFTS) is a zoonotic infectious disease caused by the severe fever with thrombocytopenia syndrome virus (SFTSV). Endemic in East Asia, SFTS is characterized by an exceptionally high mortality rate. Presently, there is no established treatment for SFTS, particularly for patients in critical condition. In this study, we collected and analyzed laboratory
-
Early extracorporeal photopheresis treatment is associated with better survival in patients with chronic or recurrent acute lung allograft dysfunction. J. Clin. Apher. (IF 1.4) Pub Date : 2024-06-01 Fiorenza Gautschi,Tobias Vogelmann,Gernot Ortmanns,Fabian Knörr,Carolin Steinack,René Hage,Mirjam Nägeli,Macé Matthew Schuurmans
BACKGROUND Due to development of chronic lung allograft dysfunction (CLAD), prognosis for patients undergoing lung transplantation (LTx) is still worse compared to other solid organ transplant recipients. Treatment options for slowing down CLAD progression are scarce with extracorporeal photopheresis (ECP) as an established rescue therapy. The aim of the study was to identify characteristics of responders
-
Optimizing autologous stem cell collections for patients with multiple myeloma receiving G‐CSF and Plerixafor: A single center project J. Clin. Apher. (IF 1.4) Pub Date : 2024-05-28 Ayda Javanbakht, Stephanie Stringer, Hollie Anderson, Ellie Hamilton, Anisha Philip, Edmund K. Waller, Amelia A. Langston, Nisha Joseph, John D. Roback, Thomas Schneider, H. Cliff Sullivan, Jeanne E. Hendrickson
BackgroundIncreasing indications for cellular therapy collections have stressed our healthcare system, with autologous collections having a longer than desired wait time until apheresis collection. This quality improvement initiative was undertaken to accommodate more patients within existing resources.Study Design and MethodsPatients with multiple myeloma who underwent autologous peripheral blood
-
Successful management of maternal anti‐PP1Pk alloimmunization in pregnancy with therapeutic plasma exchange and intravenous immunoglobulin J. Clin. Apher. (IF 1.4) Pub Date : 2024-05-11 Yannis Hadjiyannis, Jennifer M. Jones, Irina Chibisov, Joseph Kiss, Kim Gabert, Joan Sevcik, Suzanne Bakdash, Anna Binstock, Carolyn Kilonsky, Kristiina Parviainen, Alesia Kaplan
Anti‐PP1PK alloimmunization is rare given ubiquitous P1PK expression. Prevention of recurrent miscarriages and hemolytic disease of the fetus and newborn (HDFN) in pregnant individuals with anti‐PP1PK antibodies has relied upon individual reports. Here, we demonstrate the successful management of maternal anti‐PP1PK alloimmunization in a 23‐year‐old, G2P0010, with therapeutic plasma exchange (TPE)
-
Therapeutic apheresis in kidney transplantation: Emerging trends J. Clin. Apher. (IF 1.4) Pub Date : 2024-05-06 Chimezie Godswill Okwuonu, Monarch Shah, Iram Rafique, Abdallah Saleh Abdelrazeq, Jeanne Kamal, Swati Rao, Rasheed Abiodun Balogun
IntroductionThe use of therapeutic apheresis (TA) either as stand‐alone or adjunctive treatment in kidney transplantation has increased over the years to become a leading indication. This study shows recent trends in indications for TA related to kidney transplantation, adverse events, and patient outcome in this cohort.MethodsThis is a retrospective cohort review of adults who received TA for kidney
-
Comparison of peripheral blood automated hematopoietic progenitor cell count and flow cytometric CD34+ cell count J. Clin. Apher. (IF 1.4) Pub Date : 2024-05-06 Mischa Hagenkötter, Thomas Mika, Swetlana Ladigan‐Badura, Karin Schork, Martin Eisenacher, Roland Schroers, Alexander Baraniskin
BackgroundStem cell apheresis in the context of autologous stem cell transplantation requires an accurate cluster of differentiantion 34 (CD34+) count determined by flow cytometry as the current gold standard. Since flow cytometry is a personnel and time‐intensive diagnostic tool, automated stem cell enumeration may provide a promising alternative. Hence, this study aimed to compare automated hematopoietic
-
Optimization of single‐needle red cell exchange in patients with sickle cell disease J. Clin. Apher. (IF 1.4) Pub Date : 2024-04-29 Lilora Kearney, Regina Bosnick, Haley Phillips, Amanda Ghio, Dierdre Cullen, Lori Sweat, Yan Zheng
The hypercoagulable state associated with sickle cell disease (SCD) can be challenging for apheresis procedures. Among 62 single‐needle red cell exchanges (SN‐RCEs) performed over a 15‐month period, 4 patients experienced 6 hemolytic events with a discolored plasma layer, elevated plasma/RBC interface in the centrifuge, and accompanying alarms of “Cells were detected in plasma line from centrifuge”
-
Recurrent clumping in the extracorporeal photopheresis circuit using acid citrate dextrose solution A J. Clin. Apher. (IF 1.4) Pub Date : 2024-04-25 Yandy Marx Castillo‐Aleman, Shinnette Lumame, Charisma Castelo, Ruqqia Mir, Yendry Ventura‐Carmenate, Fatema Mohammed Al‐Kaabi
-
Therapeutic plasma exchange as an intervention for gemtuzumab ozogamicin impaired hemoglobin scavenging: A case and systematic review J. Clin. Apher. (IF 1.4) Pub Date : 2024-04-22 Brian D. Adkins, Daniel K. Noland, Tamra Slone, Arhanti Sadanand
Gemtuzumab ozogamicin (GO) is a CD33 monoclonal antibody‐drug conjugate currently in use to treat myeloid malignancies. A unique adverse effect of this medication is destruction of CD33 positive macrophages resulting in reduced clearance of free hemoglobin leading to grossly red plasma. This build‐up of free hemoglobin can potentially lead to end organ damage and prevent performance of clinically necessary
-
Assessing the clinical efficacy of low‐volume therapeutic plasma exchange in achieving recovery from acute liver failure induced by yellow phosphorous poisoning J. Clin. Apher. (IF 1.4) Pub Date : 2024-04-18 Ancy Ninan, Ganesh Mohan, Vishal Shanbhag, Deepika Chenna, Shamee Shastry, Shwethapriya Rao
BackgroundAcute liver failure (ALF) following yellow phosphorous (YP) ingestion is similar to acetaminophen‐induced ALF and it has become a public concern in our region. This study assessed low volume therapeutic plasma exchange (LV‐TPE) efficacy in improving the transplant free survival in YP poisoning.MethodsAdult patients with toxicology reports of YP and ALF requiring critical care were included
-
Beyond traditional venous access: Midline catheter use in pediatric apheresis J. Clin. Apher. (IF 1.4) Pub Date : 2024-04-18 Kira Geile, Kevin Barton, Raja Dandamudi
The objective of this study was to assess the use of midline catheters as venous access for apheresis procedures in pediatric patients. A retrospective analysis of medical records was conducted from September 2019 to June 2022 to evaluate the safety and efficacy of midline catheters for therapeutic pediatric apheresis. During the study period, a total of 121 procedures were inserted in 22 unique patients
-
Collection efficiency of double‐ versus single‐needle extracorporeal photopheresis J. Clin. Apher. (IF 1.4) Pub Date : 2024-04-18 Yandy Marx Castillo‐Aleman, Shinnette Lumame, Charisma Castelo, Yendry Ventura‐Carmenate, Fatema Mohammed Al‐Kaabi
-
Suspected autoimmune encephalitis: A retrospective study of patients referred for therapeutic plasma exchange J. Clin. Apher. (IF 1.4) Pub Date : 2024-04-18 Elizabeth P. Crowe, Luisa A. Diaz‐Arias, Ralph Habis, Sonja O. Vozniak, Romergryko G. Geocadin, Arun Venkatesan, Aaron A.R. Tobian, John C. Probasco, Evan M. Bloch
IntroductionAutoimmune encephalitis (AE) comprises a heterogeneous group of autoantibody‐mediated disorders targeting the brain parenchyma. Therapeutic plasma exchange (TPE), one of several first‐line therapies for AE, is often initiated when AE is suspected, albeit prior to an established diagnosis. We sought to characterize the role of TPE in the treatment of suspected AE.MethodsA single‐center,
-
Apheresis practice variation during the COVID‐19 pandemic: Results of a survey J. Clin. Apher. (IF 1.4) Pub Date : 2024-04-18 Yvette C. Tanhehco, Mohamed Alsammak, Vishesh Chhibber, Nnaemeka Ibeh, Yanhua Li, Laura D. Stephens, Daniel K. Noland, Ding Wen Wu, Nicole D. Zantek, Phillip J. DeChristopher, Marisa Claudia Saint Martin, Wen Lu, Gay Wehrli
BackgroundThe COVID‐19 pandemic affected healthcare delivery across all specialties including apheresis. To describe the changes in apheresis service practices that occurred during the pandemic, the American Society for Apheresis (ASFA) Apheresis Medicine Attending Physician Subcommittee conducted a survey study.Study Design and MethodsA 32‐question survey was designed and distributed to 400 ASFA physician
-
-
Special Issue Abstracts from the American Society for Apheresis 45th Annual Meeting April 17–19, 2024 J. Clin. Apher. (IF 1.4) Pub Date : 2024-04-13
-
-
Improved survival in COVID‐19 related sepsis and ARDS treated with a unique “triple therapy” including therapeutic plasma exchange: A single center retrospective analysis J. Clin. Apher. (IF 1.4) Pub Date : 2024-02-26 Philip Keith, Rebecca Inez Caldino Bohn, Trung Nguyen, L. Keith Scott, Monty Richmond, Matthew Day, Carol Choe, Linda Perkins, Rebecca Burnside, Richard Pyke, Ben Rikard, Amanda Guffey, Arun Saini, H. J. Park, Joseph Carcillo
BackgroundThroughout the COVID‐19 pandemic, the mortality of critically ill patients remained high. Our group developed a treatment regimen targeting sepsis and ARDS which we labeled “triple therapy” consisting of (1) corticosteroids, (2) therapeutic plasma exchange (TPE), and (3) timely intubation with lung protective ventilation. Our propensity analysis assesses the impact of triple therapy on survival
-
Writing manuscripts for peer review J. Clin. Apher. (IF 1.4) Pub Date : 2024-02-23 Robert Weinstein
Little instruction in writing manuscripts for peer review is provided in nursing school or medical school. To relatively inexperienced would‐be authors, including junior physicians and allied health professionals, this avenue of professional communication may sometimes seem to be unattainable. Yet many of them are energetic and insightful, and have the potential to make contributions to the literature
-
Real-world evidence of heparin and citrate use in extracorporeal photopheresis: A hypothesis-generating data review of device settings and performance J. Clin. Apher. (IF 1.4) Pub Date : 2024-02-14 Laura S. Connelly-Smith, James Griffin, Albert T. Leung, Francesca Gennari
Extracorporeal photopheresis (ECP) is widely used for the treatment of cutaneous T-cell lymphoma, graft-vs-host disease, and other immune-related conditions. To avoid clotting during treatment, the ECP system used must be effectively primed with an anticoagulant. Heparin is the recommended anticoagulant for the THERAKOS CELLEX System, but acid citrate dextrose-A (ACDA) is often used. We compared system
-
Use of therapeutic plasma exchange to remove lipoprotein X in a patient with vanishing bile duct syndrome presenting with cholestasis, pseudohyponatremia, and hypercholesterolemia: A case report and review of literature J. Clin. Apher. (IF 1.4) Pub Date : 2024-02-09 Yujung Jung, Heather A. Nelson, David Ming-Hung Lin
Lipoprotein X (Lp-X) is an abnormal lipoprotein found in multiple disease conditions, including liver dysfunction and cholestasis. High Lp-X concentrations can interfere with some laboratory testing that may result in spurious results. The detection of Lp-X can be challenging, and there is currently a lack of consensus regarding the management of Lp-X other than treating the underlying disease.
-
Evaluation of a scoring system for vein suitability in platelet apheresis donors J. Clin. Apher. (IF 1.4) Pub Date : 2024-02-09 Shahida Noushad, Abhishekh Basavarajegowda, Esha Toora, Dibyajyoti Sahoo, K M Hari Priya
Donor vein assessment for the selection of good quality veins is crucial for a successful apheresis procedure. This study intends to find out the effectiveness of a vein assessment scoring tool (VST) used and found to be effective in selecting whole blood donors to reduce the difficulty in identifying good quality veins for the plateletpheresis procedure.
-
Safety and efficacy of peripheral blood stem cells collection in healthy children and pediatric patients with thalassemia major weighing 20 kg or less J. Clin. Apher. (IF 1.4) Pub Date : 2024-01-08 Libai Chen, Jianyun Wen, Xiaoxiao Xu, Jing Du, Yongsheng Ruan, Xiaoqin Feng, Juan Li, Yuelin He, Xuedong Wu
Peripheral blood stem cell (PBSC) collection in children poses challenges due to their small size, low body weight (BW), and unique pediatric physiology, especially among children weighing 20 kg (kg) or less.
-
A single center retrospective study: Comparison between centrifugal separation plasma exchange with ACD-A and membrane separation plasma exchange with heparin on acute liver failure and acute on chronic liver failure J. Clin. Apher. (IF 1.4) Pub Date : 2023-12-14 Xin-Fang Zhu, Jia-Qiang Li, Tian-Tian Liu, Yuan Wang, Yao Zhong, Qing-Mei Gao, Qi Zhang, Kang-Kang Yu, Chong Huang, Ning Li, Qing Lu, Wen-Hong Zhang, Ji-Ming Zhang, Rong Xia, Jian-Ming Zheng
The purpose of this retrospective study is to compare the efficacy and safety of the centrifugal separation therapeutic plasma exchange (TPE) using citrate anticoagulant (cTPEc) with membrane separation TPE using heparin anticoagulant (mTPEh) in liver failure patients. The patients treated by cTPEc were defined as cTPEc group and those treated by mTPEh were defined as mTPEh group, respectively. Clinical
-
MicroRNA and granulocyte-monocyte adsorption apheresis combotherapy after inadequate response to anti-TNF agents in ulcerative colitis J. Clin. Apher. (IF 1.4) Pub Date : 2023-12-06 Esteban Sáez-González, Inés Moret-Tatay, Guillermo Bastida, Mariam Aguas, Marisa Iborra, Pilar Nos, Belén Beltrán
Ulcerative colitis (UC) is an inflammatory bowel disease characterized by chronic inflammation of the gastrointestinal tract, affecting millions of individuals throughout the world, and producing an impaired health-related quality of life. Granulocyte and monocyte apheresis (GMA) is a therapeutic option for UC management to induce remission by selective removal of activated leukocytes from bloodstream
-
Validation of Nivestym compared to Neupogen: An NMDP analysis J. Clin. Apher. (IF 1.4) Pub Date : 2023-12-01 Joseph Maakaron, Katie Picotte, Kevin Tram, Ruth Bakken, Jason Oakes, Meghann Cody, John Miller, Steven M. Devine, Heather E. Stefanski
1 INTRODUCTION The Coronavirus Disease 2019 (COVID-19) pandemic in early 2020 resulted in multiple challenges for the NMDP. At the time, the Investigational New Drug (IND) protocol for peripheral blood stem cell (PBSC) mobilization was limited to the use of Neupogen (NP) (Amgen, CA), which created logistical problems on the supply side as it was difficult to rely on only one medication for mobilization
-
Therapeutic plasma exchange in refractory Susac's syndrome: A brief report J. Clin. Apher. (IF 1.4) Pub Date : 2023-11-21 Ryan D. Salazar, Krystol R. Weidner, Caroline R. Alquist
Susac's syndrome (SuS) is an autoimmune endotheliopathy that typically presents with the clinical triad of encephalopathy, hearing loss, and branch retinal artery occlusion. It has a wide range of possible presentations, and its pathogenesis remains uncertain. Fulminant and refractory cases are difficult to treat, and no standard treatment protocol has been established. However, therapeutic plasma
-
A retrospective study to investigate the efficacy and safety of granulocyte and monocyte adsorptive apheresis in patients with primary sclerosing cholangitis with ulcerative colitis J. Clin. Apher. (IF 1.4) Pub Date : 2023-11-21 Ayumi Ito, Shun Murasugi, Maria Yonezawa, Teppei Omori, Shinichi Nakamura, Katsutoshi Tokushige
Primary sclerosing cholangitis has a poor prognosis and can be accompanied by ulcerative colitis. Infection control is essential, so immunosuppressive drugs should ideally be preferably. Granulocyte and monocyte adsorptive apheresis does not suppress the immune system and is used to treat ulcerative colitis. Therefore, this study investigated the efficacy and safety of granulocyte and monocyte adsorptive
-
Fractionated plasma separation and adsorption integrated with continuous veno-venous hemofiltration in patients with acute liver failure: A single center experience from China J. Clin. Apher. (IF 1.4) Pub Date : 2023-11-20 Jianhua Dong, Li Huang, Chuan Li, Bian Wu, Xi Yang, Yongchun Ge
To evaluate the clinical efficacy and safety of fractionated plasma separation and adsorption integrated with continuous veno-venous hemofiltration (FPSA-CVVH) treatment in patients with acute liver failure (ALF).
-
Crude collection efficiency of CD34+ hematopoietic stem cell apheresis J. Clin. Apher. (IF 1.4) Pub Date : 2023-11-08 Yandy Marx Castillo-Aleman
Understanding the apheresis principles for harvesting hematopoietic stem cells (HSCs) is critical for performing efficient procedures. However, despite significant advances in estimating the collection efficiency (CE) of aphereses, many confounding factors still need to be addressed in the classical calculations. The CE values are unrestricted, and many procedures exhibit CEs of a given cell population
-
Vascular access for autologous peripheral blood stem cells collection by large volume leukapheresis: Single center experience J. Clin. Apher. (IF 1.4) Pub Date : 2023-11-08 Ines Bojanić, Greta Novosel, Marijana Lukač Baričević, Petar Škrnjug, Elena Horvat, Sanja Mazić, Josip Batinić, Sandra Bašić Kinda, Branka Golubić Ćepulić
Peripheral blood stem cell (PBSC) harvesting requires reliable and safe vascular access. In our institution, a change of practice was implemented and the central venous catheter (CVC) placement for all autologous PBSC collections was abandoned in favor of a careful evaluation of peripheral venous access (PVA) for each individual patient. The aim of this prospective study was to evaluate the rate of
-
Comorbidity in lipoprotein apheresis: Their role in the era of new lipid-lowering therapies J. Clin. Apher. (IF 1.4) Pub Date : 2023-10-19 Francesco Sbrana, Mascia Pianelli, Roberta Luciani, Federico Bigazzi, Carmen Corciulo, Andrea Ripoli, Tiziana Sampietro, Beatrice Dal Pino
Despite advance in pharmacotherapy of lipid disorders, lipoprotein apheresis (LA) plays a leading role in the management of severe hypercholesterolemia and in atherosclerosis prevention.
-
Therapeutic plasma exchange for mechanical red cell hemolysis: A case series J. Clin. Apher. (IF 1.4) Pub Date : 2023-10-18 Chloe E. Douglas, Taylor R. House, Larissa Yalon, Shina Menon
We present three cases of severely elevated plasma free hemoglobin (PFH) in pediatric patients on mechanical circulatory support devices at a tertiary pediatric care center. Due to severe levels of PFH in the setting of critical illness with the inability to pursue immediate mechanical device exchange, membrane filtration therapeutic plasma exchange (TPE) was performed, which resulted in a lowering
-
Hyperchloremic metabolic acidosis after plasma exchange in a patient with renal transplant rejection: A case report J. Clin. Apher. (IF 1.4) Pub Date : 2023-10-06 S.S.A. Simon, M.S. van Sandwijk, R.H.G. Olde Engberink
Therapeutic plasma exchange (TPE) is an effective treatment for several renal disorders, including renal transplant rejection. However, repeated plasma exchanges can result in various metabolic disturbances and complications. We present a 61-year old male with a medical history of type 2 diabetes, hypertension, successfully treated multiple myeloma, and a post-mortem kidney transplantation 7 months
-
Effectiveness of leukapheresis on early survival in acute myeloid leukemia: An observational propensity score matching cohort study J. Clin. Apher. (IF 1.4) Pub Date : 2023-10-03 Howon Lee, Jay Ho Han, Jae Kwon Kim, Jaeeun Yoo, Hyung Suk Cho, Jae-Ho Yoon, Byung Sik Cho, Hee-Je Kim, Jihyang Lim, Dong Wook Jekarl, Yonggoo Kim
The association between leukapheresis (LK) as a treatment option for hyperleukocytosis (HL) in patients with acute myeloid leukemia (AML) remains controversial.
-
Adsorptive cytapheresis in ulcerative colitis: A non-pharmacological therapeutic approach revisited J. Clin. Apher. (IF 1.4) Pub Date : 2023-10-03 Filippo Vernia, Angelo Viscido, Giovanni Latella
Adsorptive cytapheresis proves effective in a proportion of patients affected by ulcerative colitis. Relatively high cost and the need for apheresis facilities, prevented the widespread use of this therapeutic approach. More so following the introduction of anti-TNFα biosimilars which proved both effective and inexpensive. Anti-TNFα agents, however, are burdened by high rate of primary and secondary
-
Updates on the mobilization pipeline for hematopoietic stem cell collection J. Clin. Apher. (IF 1.4) Pub Date : 2023-09-25 Minh-Ha Tran, Muharrem Yunce
Hematopoetic Stem Cell Transplantation is a life saving procedure which requires mobilization of stem cells for apheresis procedure. In this review we aimed to examine mobilizing agents that are in use and under investigation. Apheresis practitioners who oversee stem cell collections should be familiar with the recent advances in mobilization agents to utilize most up-to-date information for better
-
Therapeutic plasma exchange decreases plasma anti-SARS-CoV-2 spike IgG without increasing the proximate incidence of COVID-19 J. Clin. Apher. (IF 1.4) Pub Date : 2023-09-14 Jensyn Cone Sullivan, Steven E. Conklin, Stephanie Conrad, Coby Horowitz, Mark Diethelm, Raymond Comenzo
Therapeutic plasma exchange (TPE) removes both pathologic and protective immunoglobulins (Ig). SARS-CoV-2 immunity is partially mediated by anti-SARS-CoV-2 spike antibodies (SAb), which impair viral host-cell invasion. Nonetheless, the systematic effect of TPE on SAb concentration and SARS-CoV-2 immunity is unknown.
-
Immunity in the balance: Fatal disseminated adenovirus infection in a patient undergoing plasma exchange and immunosuppressive chemotherapy for anti-glomerular basement membrane disease J. Clin. Apher. (IF 1.4) Pub Date : 2023-09-12 Jeremy W. Jacobs, Cristina A. Figueroa Villalba, Kristin Stendahl, Christopher A. Tormey, Elizabeth Abels
Anti-glomerular basement membrane (anti-GBM) disease (formerly known as Goodpasture's syndrome) is a rare autoinflammatory condition that affects the renal and/or pulmonary capillaries. The standard therapeutic regimen for anti-GBM disease involves therapeutic plasma exchange (TPE), cyclophosphamide, and corticosteroids to rapidly remove and inhibit autoantibody production and reduce organ inflammation
-
The first reported use of red blood cell exchange to treat hemoglobin Evans with secondary methemoglobinemia J. Clin. Apher. (IF 1.4) Pub Date : 2023-09-04 Lance A. Williams, Jill Adamski, Theresa N. Kinard, Natalie M. Ertz-Archambault, Qun Lu, Kristin Gray, Jennifer L. Herrick, Leon Su, Leslie Padrnos
This manuscript describes a novel approach for treating patients with long-term sequelae from hemoglobin Evans (Hb Evans). After instituting conservative therapies for approximately 2 years, our patient's symptoms continually worsened. Therefore, we performed red blood cell exchange (RBCx) to reduce his Hb Evans percentage and his co-existing elevation of methemoglobin. Our assumptions of clinical
-
The impact of the COVID-19 pandemic on source plasma donations J. Clin. Apher. (IF 1.4) Pub Date : 2023-08-22 Mischa L. Covington, Chesinta Voma, Sean R. Stowell
While the COVID-19 pandemic has impacted many aspects of healthcare, including routine blood donations, the impact of COVID-19 on the donation of source plasma critical to many aspects of patient care, including apheresis procedures, has been more difficult to define. As production of plasma-derived medicinal products (PDMPs) can take up to a year, shortages in source plasma donations may not be immediately
-
Baseline inflammation indexes and neutrophil-to-LDH ratio for prediction of the first mobilization failure without plerixafor-based regimens in multiple myeloma and lymphoma patients: A single-center retrospective study J. Clin. Apher. (IF 1.4) Pub Date : 2023-08-14 Ahmet Burak Dirim, Tarik Onur Tiryaki, Soner Altin, Sevgi Kalayoglu Besisik, Ipek Yonal Hindilerden, Meliha Nalcaci
Many factors were identified for mobilization failure (MF) in autologous hematopoietic stem-cell transplantation. To our knowledge, this is the first study to investigate the efficacy of baseline inflammation indexes and neutrophil-to-lactate dehydrogenase (LDH) ratio to predict MF in multiple myeloma (MM) and lymphoma.
-
Francis S. Morrison MD—Tribute to an apheresis leader J. Clin. Apher. (IF 1.4) Pub Date : 2023-08-10 Walter Linz, James T. Thigpen, Ronald G. Strauss
Francis S. Morrison MD was among the early developers and promoters of the American Society for Apheresis (ASFA). His work was pivotal in creating a lasting institutional structure from which American apheresis medical practice would develop decades after his death. Francis Morrison is honored each year at the ASFA annual meeting as ASFA awards the Francis S. Morrison MD Memorial Award Lecture to an